Published in News

Cambridge-1 switched on

by on09 July 2021

Speeding up disease treatment

A British supercomputer, backed by some of Nvidia’s hottest, sorry finest, chips has been switched on and is busy making the process of preventing, diagnosing and treating disease better, faster and cheaper.

Dubbed Cambridge-1, the supercomputer represents a $100m investment by US-based computing company Nvidia. The idea capitalises on artificial intelligence (AI) -- which combines big data with computer science to facilitate problem-solving -- in healthcare.

Cambridge-1's first projects will be with AstraZeneca, GSK, Guy's and St Thomas' NHS foundation trust, King's College London and Oxford Nanopore. They will seek to develop a deeper understanding of diseases such as dementia, design new drugs, and improve the accuracy of finding disease-causing variations in human genomes.

Dr Kim Branson, global head of artificial intelligence and machine learning at GSK,  said that the supercomputer will help in the field of immuno-oncology where existing medicines harness the patient's own immune system to fight cancer.

Cambridge-1 can be key to helping fuse these different datasets, and building large models to help determine the best course of treatment for patients, Branson said.


Last modified on 09 July 2021
Rate this item
(0 votes)

Read more about: